Scopio Labs, a developer of Full-Field Digital Cell Morphology imaging and analysis platforms, raised its Series D funding round of $42 million led by Fortissimo Capital, with participation from OurCrowd, Aurum Ventures MKI, OTV, and LR Group.
The newly secured capital will be used to fuel commercial expansion and accelerate the innovation of new products that leverage Scopio's Full-Field technology.
Scopio's breakthrough platform utilizes computational photography to provide unprecedented digital imaging of thousands of cells. It gives lab practitioners a full-field view of all regions of clinical interest on the sample at the highest resolution, eliminating the need for manual microscopy. By combining the power of clinical AI-based decision support with Full-Field digital imaging, Scopio delivers unparalleled workflow efficiency in blood cell analysis. This approach is designed to enhance remote consultation and collaboration, expedite decision-making, and improve patient care.
The funding will also support the continued development of Scopio Labs' digital morphology platform and the creation of next-generation products to meet the evolving needs of hematology laboratories and hospitals.
Scopio Labs' Full-Field imaging technology is driving the digital transformation of hematology laboratories worldwide. By providing laboratory scientists and clinicians with unprecedented scale and depth in digital cell morphology, the company's platforms enable timely detection of blood-related medical conditions, expediting patients' access to life-saving treatments. Scopio's high-resolution imaging and embedded AI combine to create a more efficient remote workflow, contributing to better diagnostics across the continuum of care.
